Delcath Systems (DCTH) Stock Price, News & Analysis

Company Overview

Delcath Systems, Inc. is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma. Delcath’s approach aims to improve tumor response rates and extend progression-free survival for patients with limited treatment options.

The Hepatic CHEMOSAT® Delivery System comprises specialized catheters, an extracorporeal filtration system and an isolation balloon that together isolate the liver’s vasculature, deliver high-dose chemotherapy and filter the returned blood before it reenters the patient’s systemic circulation. Delcath has achieved CE Mark approval in Europe for the treatment of unresectable liver tumors and is advancing its clinical development program in the United States, where it has completed pivotal trials assessing safety and efficacy in patients with ocular melanoma metastases in the liver. The company also continues to explore expanded indications and next-generation applications of its chemosaturation platform.

Headquartered in New York, Delcath Systems operates in key oncology markets across North America and Europe, collaborating with leading cancer centers and interventional radiology departments. The organization is guided by a management team and board of directors with experience in medical device commercialization, oncology drug development and regulatory affairs. Delcath remains committed to advancing targeted regional therapies that address unmet needs in the treatment of liver tumors and improving patient outcomes through innovation and rigorous clinical investigation.

Key Stats

• Today's Range: $11.43 to $11.68
• 50-Day Range: $8.60 to $11.53
• 52-Week Range: $8.12 to $18.23
• Volume: 148,589 shs
• Average Volume: 416,687 shs
• Market Capitalization: $395.08 million
• P/E Ratio: 163.83
• Dividend Yield: N/A
• Price Target: $22.50
• Consensus Rating: Moderate Buy

Delcath Systems Stock Analysis - MarketRank™

Delcath Systems scored higher than 30% of companies evaluated by MarketBeat, and ranked 694th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Delcath Systems has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Delcath Systems has a consensus price target of $22.50, representing about 95.8% upside from its current price of $11.49.

Amount of Analyst Coverage

Delcath Systems has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Delcath Systems are expected to grow in the coming year, from ($0.86) to $0.10 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Delcath Systems is 164.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of Delcath Systems is 164.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.35.

Price to Book Value per Share Ratio

Delcath Systems has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.90% of the float of Delcath Systems has been sold short.

Short Interest Ratio / Days to Cover

Delcath Systems has a short interest ratio ("days to cover") of 13.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Delcath Systems has recently decreased by 2.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Delcath Systems does not currently pay a dividend.

Dividend Growth

Delcath Systems does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Delcath Systems this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Delcath Systems insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.36% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DCTH Stock Analysis - Frequently Asked Questions

How have DCTH shares performed this year?

Delcath Systems' stock was trading at $10.10 at the start of the year. Since then, DCTH shares have increased by 13.8% and is now trading at $11.49.

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings results on Thursday, February, 26th. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The firm earned $20.73 million during the quarter, compared to analysts' expectations of $20.35 million. Delcath Systems had a trailing twelve-month return on equity of 2.63% and a net margin of 3.17%.
Read the conference call transcript.

When did Delcath Systems' stock split?

Delcath Systems shares reverse split on the morning of Tuesday, October 22nd 2019.The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How will Delcath Systems' stock buyback program work?

Delcath Systems' board authorized a share buyback plan on Thursday, November 20th 2025, which authorizes the company to repurchase $25,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 8.6% of its shares through open market purchases. Shares buyback plans are often a sign that the company's management believes its shares are undervalued.

Who are Delcath Systems' major shareholders?

Delcath Systems' top institutional investors include Bank of New York Mellon Corp (0.29%), Allspring Global Investments Holdings LLC (0.09%) and Leonteq Securities AG (0.03%). Insiders that own company stock include Gil Aharon, Rosalind Advisors, Inc, Gerard J Michel, Vojo Vukovic, John Purpura, Sandra Pennell and John Richard Sylvester.
View institutional ownership trends.

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Delcath Systems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Delcath Systems investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Zomedica (ZOM), Wells Fargo & Company (WFC), Wayfair (W) and Bank of America (BAC).

Company Calendar

• Last Earnings: 2/26/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:DCTH
• CIK: 872912
• Web: delcath.com
• Phone: 212-489-2100
• Fax: 212-489-2102
• Employees: 60
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Delcath Systems: $22.50
• High Price Target: $30.00
• Low Price Target: $18.00
• Potential Upside/Downside: +96.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.07
• Trailing P/E Ratio: 163.57
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $2.70 million
• Net Margins: 3.17%
• Pretax Margin: 4.12%
• Return on Equity: 2.63%
• Return on Assets: 2.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.92
• Quick Ratio: 9.98

Sales & Book Value

• Annual Sales: $85.23 million
• Price / Sales: 4.63
• Cash Flow: $0.05 per share
• Price / Cash Flow: 210.81
• Book Value: $3.15 per share
• Price / Book: 3.63

Miscellaneous

• Outstanding Shares: 34,460,000
• Free Float: 27,785,000
• Market Cap: $394.57 million
• Optionable: Optionable
• Beta: 0.54